Skip to main content
SpringerLink
Log in

Benefit of re-operation and salvage therapies for recurrent glioblastoma multiforme: results from a single institution

  • Clinical Study
  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Abstract

The optimal management of recurrent glioblastoma (GBM) has yet to be determined. We aim to assess the benefits of re-operation and salvage therapies (chemotherapy and/or re-irradiation) for recurrent GBM and to identify prognostic factors associated with better survival. All patients who underwent surgery for GBM between January 2005 and December 2012 followed by adjuvant radiotherapy, and who developed GBM recurrence on imaging were included in this retrospective study. Univariate and multivariate analysis was performed using Cox models in order to identify factors associated with overall survival (OS). One hundred and eighty patients treated to a dose of 60 Gy were diagnosed with recurrent GBM. At a median follow-up time of 6.2 months, the median survival (MS) from time of recurrence was 6.6 months. Sixty-nine patients underwent repeat surgery for recurrence based on imaging. To establish the benefits of repeat surgery and salvage therapies, 68 patients who underwent repeat surgery were matched to patients who did not based on extent of initial resection and presence of subventricular zone involvement at recurrence. MS for patients who underwent re-operation was 9.6 months, compared to 5.3 months for patients who did not have repeat surgery (p < 0.0001). Multivariate analysis in the matched pairs confirmed that repeat surgery with the addition of other salvage treatment can significantly affect patient outcome (HR 0.53). Re-operation with additional salvage therapies for recurrent GBM provides survival prolongation at the time of progression.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Minniti G et al (2010) Patterns of failure and comparison of different target volume delineations in patients with glioblastoma treated with conformal radiotherapy plus concomitant and adjuvant temozolomide. Radiother Oncol 97(3):377–381

    Article  CAS  PubMed  Google Scholar 

  2. Batchelor TT et al (2013) Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. J Clin Oncol 31(26):3212–3218

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Wick W et al (2010) Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. J Clin Oncol 28(7):1168–1174

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Reardon DA et al (2012) Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naive, recurrent glioblastoma. J Neurooncol 107(1):155–164

    Article  CAS  PubMed  Google Scholar 

  5. Wong ET et al (1999) Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 17(8):2572–2578

    Article  CAS  PubMed  Google Scholar 

  6. Brandes AA et al (2004) Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). J Clin Oncol 22(23):4779–4786

    Article  CAS  PubMed  Google Scholar 

  7. Kappelle AC et al (2001) PCV chemotherapy for recurrent glioblastoma multiforme. Neurology 56(1):118–120

    Article  CAS  PubMed  Google Scholar 

  8. Friedman HS et al (2009) Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27(28):4733–4740

    Article  CAS  PubMed  Google Scholar 

  9. Kreisl TN et al (2009) Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 27(5):740–745

    Article  CAS  PubMed  Google Scholar 

  10. Vredenburgh JJ et al (2007) Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 25(30):4722–4729

    Article  CAS  PubMed  Google Scholar 

  11. Easaw JC et al (2011) Canadian recommendations for the treatment of recurrent or progressive glioblastoma multiforme. Curr Oncol 18(3):e126–e136

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Network, NCCN Clinical Practise Guidelines in Oncology: central nervous system. (2014) http://www.nccn.org.

  13. Niyazi M et al (2012) Irradiation and bevacizumab in high-grade glioma retreatment settings. Int J Radiat Oncol Biol Phys 82(1):67–76

    Article  CAS  PubMed  Google Scholar 

  14. Ciammella P et al (2013) Hypofractionated stereotactic radiation therapy for recurrent glioblastoma: single institutional experience. Radiat Oncol 8(1):222

    Article  PubMed  PubMed Central  Google Scholar 

  15. Park KJ et al (2012) Salvage gamma knife stereotactic radiosurgery followed by bevacizumab for recurrent glioblastoma multiforme: a case-control study. J Neurooncol 107(2):323–333

    Article  CAS  PubMed  Google Scholar 

  16. Cuneo KC et al (2012) Safety and efficacy of stereotactic radiosurgery and adjuvant bevacizumab in patients with recurrent malignant gliomas. Int J Radiat Oncol Biol Phys 82(5):2018–2024

    Article  CAS  PubMed  Google Scholar 

  17. Gutin PH et al (2009) Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas. Int J Radiat Oncol Biol Phys 75(1):156–163

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Combs SE et al (2005) Stereotactically guided fractionated re-irradiation in recurrent glioblastoma multiforme. J Neurooncol 74(2):167–171

    Article  CAS  PubMed  Google Scholar 

  19. Nieder C et al (2008) Improvement, clinical course, and quality of life after palliative radiotherapy for recurrent glioblastoma. Am J Clin Oncol 31(3):300–305

    Article  PubMed  Google Scholar 

  20. McKenzie JT et al (2013) Hypofractionated stereotactic radiotherapy for unifocal and multifocal recurrence of malignant gliomas. J Neurooncol 113(3):403–409

    Article  CAS  PubMed  Google Scholar 

  21. Ruben JD et al (2006) Cerebral radiation necrosis: incidence, outcomes, and risk factors with emphasis on radiation parameters and chemotherapy. Int J Radiat Oncol Biol Phys 65(2):499–508

    Article  PubMed  Google Scholar 

  22. Hall WA et al (1995) Stereotactic radiosurgery for recurrent malignant gliomas. J Clin Oncol 13(7):1642–1648

    Article  CAS  PubMed  Google Scholar 

  23. Cho KH et al (1999) Single dose versus fractionated stereotactic radiotherapy for recurrent high-grade gliomas. Int J Radiat Oncol Biol Phys 45(5):1133–1141

    Article  CAS  PubMed  Google Scholar 

  24. Combs SE et al (2005) Efficacy of fractionated stereotactic reirradiation in recurrent gliomas: long-term results in 172 patients treated in a single institution. J Clin Oncol 23(34):8863–8869

    Article  PubMed  Google Scholar 

  25. Ammirati M et al (1987) Reoperation in the treatment of recurrent intracranial malignant gliomas. Neurosurgery 21(5):607–614

    Article  CAS  PubMed  Google Scholar 

  26. Harsh, G.R.t. et al (1987) Reoperation for recurrent glioblastoma and anaplastic astrocytoma. Neurosurgery 21(5):615–621

    Article  PubMed  Google Scholar 

  27. De Bonis P et al (2013) The influence of surgery on recurrence pattern of glioblastoma. Clin Neurol Neurosurg 115(1):37–43

    Article  PubMed  Google Scholar 

  28. Park JK et al (2010) Scale to predict survival after surgery for recurrent glioblastoma multiforme. J Clin Oncol 28(24):3838–3843

    Article  PubMed  PubMed Central  Google Scholar 

  29. Park CK et al (2013) A practical scoring system to determine whether to proceed with surgical resection in recurrent glioblastoma. Neuro Oncol 15(8):1096–1101

    Article  PubMed  PubMed Central  Google Scholar 

  30. Ryken TC et al (2014) The role of cytoreductive surgery in the management of progressive glioblastoma: a systematic review and evidence-based clinical practice guideline. J Neurooncol 118(3):479–488

    Article  PubMed  Google Scholar 

  31. Barbagallo GM, Jenkinson MD, Brodbelt AR (2008) ‘Recurrent’ glioblastoma multiforme, when should we reoperate? Br J Neurosurg 22(3):452–455

    Article  PubMed  Google Scholar 

  32. De Bonis P et al (2013) The impact of repeated surgery and adjuvant therapy on survival for patients with recurrent glioblastoma. Clin Neurol Neurosurg 115(7):883–886

    Article  PubMed  Google Scholar 

  33. Mandl ES et al (2008) Repeated surgery for glioblastoma multiforme: only in combination with other salvage therapy. Surg Neurol 69(5):506–509 (discussion 509).

    Article  PubMed  Google Scholar 

  34. Barker FG 2nd et al (1998) Survival and functional status after resection of recurrent glioblastoma multiforme. Neurosurgery 42(4):709–720 (discussion 720-723).

    Article  PubMed  Google Scholar 

  35. Keles GE et al (2004) Volume of residual disease as a predictor of outcome in adult patients with recurrent supratentorial glioblastomas multiforme who are undergoing chemotherapy. J Neurosurg 100(1):41–46

    Article  PubMed  Google Scholar 

  36. Butowski NA, Sneed PK, Chang SM (2006) Diagnosis and treatment of recurrent high-grade astrocytoma. J Clin Oncol 24(8):1273–1280

    Article  CAS  PubMed  Google Scholar 

  37. Bloch O et al (2012) Impact of extent of resection for recurrent glioblastoma on overall survival: clinical article. J Neurosurg 117(6):1032–1038

    Article  PubMed  Google Scholar 

  38. Quick J et al (2014) Benefit of tumor resection for recurrent glioblastoma. J Neurooncol 117(2):365–372

    Article  CAS  PubMed  Google Scholar 

  39. Chaichana KL et al (2013) Multiple resections for patients with glioblastoma: prolonging survival. J Neurosurg 118(4):812–820

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Oncology, Division of Radiation Oncology, Cedars Cancer Centre, McGill University Health Centre, 1001 Decarie Boulevard, Montréal, QC, H4A 3J1, Canada

    M. Azoulay, G. Shenouda, V. Panet-Raymond, L. Souhami & Bassam S. Abdulkarim

  2. Department of Oncology, Division of Cancer Epidemiology, McGill University, 546 Pine Avenue West, Montréal, QC, H2W 1S6, Canada

    F. Santos

  3. Department of Neurology and Neurosurgery, Montreal Neurological Hospital, McGill University, 3801 University Avenue, Montréal, QC, H3A 2B4, Canada

    K. Petrecca

  4. Research Institute of the McGill University Health Center, Montreal General Hospital, 1625 Pine Avenue West, Montréal, QC, H3G 1A4, Canada

    A. Oweida

  5. Department of Pathology, Montreal Neurological Hospital, McGill University, 3801 University Avenue, Montréal, QC, H3A 2B4, Canada

    M. C. Guiot

  6. Department of Oncology, Division of Medical Oncology, Cedars Cancer Centre, McGill University Health Centre, 1001 Decarie Boulevard, Montréal, QC, H4A 3J1, Canada

    S. Owen

Authors
  1. M. Azoulay
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. F. Santos
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. G. Shenouda
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. K. Petrecca
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A. Oweida
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M. C. Guiot
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. S. Owen
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. V. Panet-Raymond
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. L. Souhami
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Bassam S. Abdulkarim
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Bassam S. Abdulkarim.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Azoulay, M., Santos, F., Shenouda, G. et al. Benefit of re-operation and salvage therapies for recurrent glioblastoma multiforme: results from a single institution. J Neurooncol 132, 419–426 (2017). https://doi.org/10.1007/s11060-017-2383-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11060-017-2383-2

Keywords

Search

Navigation